Shire Stock Price, News & Analysis (NASDAQ:SHPG)

$144.99 -0.70 (-0.48 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$144.99
Today's Range$143.54 - $146.05
52-Week Range$137.17 - $192.15
Volume1.14 million shs
Average Volume1.22 million shs
Market Capitalization$43.53 billion
P/E Ratio27.31
Dividend Yield0.64%
Beta1.59

About Shire (NASDAQ:SHPG)

Shire logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:SHPG
CUSIPN/A
Phone+353-1-6096000

Debt

Debt-to-Equity Ratio0.55%
Current Ratio0.98%
Quick Ratio0.52%

Price-To-Earnings

Trailing P/E Ratio27.3050847457627
Forward P/E Ratio9.67
P/E Growth0.78

Sales & Book Value

Annual Sales$11.40 billion
Price / Sales3.83
Cash Flow$16.29 per share
Price / Cash8.90
Book Value$95.20 per share
Price / Book1.52

Profitability

Trailing EPS$5.31
Net Income$327.40 million
Net Margins10.95%
Return on Equity14.41%
Return on Assets6.60%

Miscellaneous

Employees23,906
Outstanding Shares300,810,000

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire announced a semiannual dividend on Friday, August 11th. Shareholders of record on Friday, September 8th will be paid a dividend of $0.1527 per share on Friday, October 20th. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire PLC (NASDAQ:SHPG) issued its quarterly earnings results on Friday, October, 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, topping the Zacks' consensus estimate of $3.64 by $0.17. The biopharmaceutical company had revenue of $3.70 billion for the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. The firm's revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the company earned $3.17 EPS. View Shire's Earnings History.

When will Shire make its next earnings announcement?

Shire is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Shire.

What guidance has Shire issued on next quarter's earnings?

Shire updated its FY17 earnings guidance on Friday, October, 27th. The company provided earnings per share guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.92. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $14.97 billion.

Where is Shire's stock going? Where will Shire's stock price be in 2018?

14 equities research analysts have issued 1-year target prices for Shire's shares. Their predictions range from $160.00 to $245.00. On average, they expect Shire's share price to reach $212.18 in the next year. View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:

  • 1. According to Zacks Investment Research, "The sales of Mydayis did not meet Shire’s expectation while strong performance of Vyvanse, Cinryze and Elaprase continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past one year. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters." (1/2/2018)
  • 2. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
  • 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Who are some of Shire's key competitors?

Who are Shire's key executives?

Shire's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director (Age 59)
  • Thomas Dittrich, Chief Financial Officer, Executive Director (Age 53)
  • John Miller, Interim Chief Financial Officer
  • Joanne Cordeiro, Chief Human Resource Officer
  • Andreas Busch Ph.D., Executive Vice President - Head of Research and Development, Chief Scientific Officer (Age 54)
  • Gisele Dion, Chief Accounting Officer, Corporate Controller (Age 51)
  • William Mordan, General Counsel, Company Secretary (Age 47)
  • Howard Mayer M.D., Chief Medical Officer
  • Perry Sternberg, Head - U.S. Commercial (Age 48)
  • Kim Stratton, Head - International Commercial (Age 54)

Who owns Shire stock?

Shire's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.06%), Gateway Investment Advisers LLC (0.02%), Creative Planning (0.00%), Edge Wealth Management LLC (0.00%), Searle & CO. (0.00%) and Hills Bank & Trust Co. (0.00%). View Institutional Ownership Trends for Shire.

Who sold Shire stock? Who is selling Shire stock?

Shire's stock was sold by a variety of institutional investors in the last quarter, including Edge Wealth Management LLC, Leavell Investment Management Inc., First National Bank & Trust Co. of Newtown, Searle & CO., Town & Country Bank & Trust CO dba First Bankers Trust CO and Capital Asset Advisory Services LLC. View Insider Buying and Selling for Shire.

Who bought Shire stock? Who is buying Shire stock?

Shire's stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Gateway Investment Advisers LLC, Boltwood Capital Management, KCS Wealth Advisory, Creative Planning, Benjamin F. Edwards & Company Inc. and Hills Bank & Trust Co.. View Insider Buying and Selling for Shire.

How do I buy Shire stock?

Shares of Shire can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of Shire stock can currently be purchased for approximately $144.99.

How big of a company is Shire?

Shire has a market capitalization of $43.53 billion and generates $11.40 billion in revenue each year. The biopharmaceutical company earns $327.40 million in net income (profit) each year or $5.31 on an earnings per share basis. Shire employs 23,906 workers across the globe.

How can I contact Shire?

Shire's mailing address is Miesian Plaza 50-58 Baggot Street Lower, Block 2, DUBLIN, D02 HW68, Ireland. The biopharmaceutical company can be reached via phone at +353-1-6096000 or via email at [email protected]


MarketBeat Community Rating for Shire (SHPG)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  841 (Vote Outperform)
Underperform Votes:  383 (Vote Underperform)
Total Votes:  1,224
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire (NASDAQ:SHPG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.572.702.79
Ratings Breakdown: 0 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $212.18$212.18$219.25$229.10
Price Target Upside: 34.90% upside34.59% upside49.87% upside39.92% upside

Shire (NASDAQ:SHPG) Consensus Price Target History

Price Target History for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018CowenSet Price TargetBuy$225.00LowView Rating Details
1/3/2018Cantor FitzgeraldSet Price TargetBuy$222.00LowView Rating Details
1/3/2018Piper Jaffray CompaniesReiterated RatingHoldLowView Rating Details
12/20/2017Liberum CapitalReiterated RatingBuy -> HoldMediumView Rating Details
11/16/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
10/30/2017FBR & CoReiterated RatingBuy$201.00N/AView Rating Details
10/8/2017Stifel NicolausReiterated RatingBuy$245.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$196.00MediumView Rating Details
8/11/2017BarclaysDowngradeOverweight -> Equal WeightLowView Rating Details
8/9/2017Jefferies GroupReiterated RatingHold$216.00 -> $206.00LowView Rating Details
7/17/2017BTIG ResearchReiterated RatingBuy$242.00LowView Rating Details
7/13/2017Sanford C. BernsteinReiterated RatingMarket Perform$210.00LowView Rating Details
4/17/2017Goldman Sachs GroupBoost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/7/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/AView Rating Details
11/3/2016CitigroupReiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
3/30/2016Bank of AmericaReiterated RatingBuyN/AView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyN/AView Rating Details
2/8/2016Susquehanna BancsharesLower Price TargetPositive$280.00 -> $220.00N/AView Rating Details
(Data available from 1/20/2016 forward)

Earnings

Shire (NASDAQ:SHPG) Earnings History and Estimates Chart

Earnings by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ SHPG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018$3.86N/AView Earnings Details
10/27/20179/30/2017$3.64$3.81$3.70 billionViewN/AView Earnings Details
8/3/20176/30/2017$3.53$3.73$3.75 billionViewListenView Earnings Details
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
10/29/2010Q3 2010$0.98$1.16ViewN/AView Earnings Details
8/4/2010Q2 2010$0.88$1.03ViewN/AView Earnings Details
4/29/2010Q1 2010$0.84$1.01ViewN/AView Earnings Details
2/19/2010Q4 2009$0.58$1.10ViewN/AView Earnings Details
10/30/2009Q3 2009$0.48$0.49ViewN/AView Earnings Details
8/5/2009Q2 2009$0.47$0.60ViewN/AView Earnings Details
4/30/2009Q1 2009$1.08$1.28ViewN/AView Earnings Details
2/19/2009Q4 2008$1.00$1.01ViewN/AView Earnings Details
10/29/2008Q3 2008$0.87$1.17ViewN/AView Earnings Details
7/31/2008Q2 2008$0.75$0.95ViewN/AView Earnings Details
4/25/2008Q1 2008$0.72$0.74ViewN/AView Earnings Details
2/21/2008Q4 2007$0.64$0.94ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Shire (NASDAQ:SHPG) Earnings Estimates

2018 EPS Consensus Estimate: $16.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$3.97$4.01$3.99
Q2 20182$3.97$4.13$4.05
Q3 20182$4.07$4.08$4.08
Q4 20182$4.37$4.43$4.40
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Shire (NASDAQ:SHPG) Dividend Information

Most Recent Dividend:10/20/2017
Annual Dividend:$0.92
Dividend Yield:0.63%
Payout Ratio:17.33% (Trailing 12 Months of Earnings)
6.13% (Based on This Year's Estimates)
5.76% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/11/2017semiannual$0.150.21%9/7/20179/8/201710/20/2017
2/24/2017$0.773/8/20173/10/20174/25/2017
8/5/2016$0.149/7/20169/9/201610/7/2016
2/11/2016$0.673/9/20163/11/20164/12/2016
7/23/2015$0.139/2/20159/4/201510/2/2015
2/23/2015semiannual$0.570.48%3/11/20153/13/20154/14/2015
8/4/2014semiannual$0.110.09%9/3/20149/5/201410/3/2014
2/20/2014semiannual$0.510.61%3/5/20143/7/20144/8/2014
7/29/2013semiannual$0.090.16%9/4/20139/6/201310/3/2013
2/19/2013semiannual$0.440.92%3/6/20133/8/20134/9/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire (NASDAQ SHPG)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Shire (NASDAQ SHPG) News Headlines

Source:
DateHeadline
Shire Plc: Thomas Dittrich To Assume CFO Role On March 19 - Quick FactsShire Plc: Thomas Dittrich To Assume CFO Role On March 19 - Quick Facts
www.nasdaq.com - January 19 at 11:20 AM
Shire PLC (SHPG) Receives Average Recommendation of "Hold" from BrokeragesShire PLC (SHPG) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 15 at 1:48 PM
$4.03 Billion in Sales Expected for Shire PLC (SHPG) This Quarter$4.03 Billion in Sales Expected for Shire PLC (SHPG) This Quarter
www.americanbankingnews.com - January 15 at 2:38 AM
Zacks: Brokerages Anticipate Shire PLC (SHPG) to Post $3.86 EPSZacks: Brokerages Anticipate Shire PLC (SHPG) to Post $3.86 EPS
www.americanbankingnews.com - January 13 at 9:34 PM
Equities Analysts Set Expectations for Shire PLCs FY2022 Earnings (SHPG)Equities Analysts Set Expectations for Shire PLC's FY2022 Earnings (SHPG)
www.americanbankingnews.com - January 13 at 2:40 PM
How Is Bioverativ’s Alprolix Positioned Now?How Is Bioverativ’s Alprolix Positioned Now?
finance.yahoo.com - January 11 at 10:18 AM
Shire to separate ADHD drugs before possible spin-off, cuts 2020 targetShire to separate ADHD drugs before possible spin-off, cuts 2020 target
finance.yahoo.com - January 8 at 5:01 PM
Shire cuts sales outlook; still considering spinout of ADHD drugsShire cuts sales outlook; still considering spinout of ADHD drugs
finance.yahoo.com - January 8 at 5:01 PM
Shire to separate ADHD drugs ahead of possible spin-off, cuts outlookShire to separate ADHD drugs ahead of possible spin-off, cuts outlook
finance.yahoo.com - January 8 at 10:09 AM
Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare ConferenceShire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 8 at 10:09 AM
Future of Kala Pharmas dry eye drug uncertain after mixed resultsFuture of Kala Pharma's dry eye drug uncertain after mixed results
finance.yahoo.com - January 5 at 10:04 AM
Shire (SHPG) Given a $225.00 Price Target at CowenShire (SHPG) Given a $225.00 Price Target at Cowen
www.americanbankingnews.com - January 5 at 9:38 AM
Shire plc: Shire to present at the 36th Annual J.P. Morgan Healthcare ConferenceShire plc: Shire to present at the 36th Annual J.P. Morgan Healthcare Conference
www.finanznachrichten.de - January 4 at 9:54 AM
Shire (SHPG) Given a $222.00 Price Target by Cantor Fitzgerald AnalystsShire (SHPG) Given a $222.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - January 3 at 7:12 PM
Shire (SHPG) Given Hold Rating at Piper Jaffray CompaniesShire (SHPG) Given Hold Rating at Piper Jaffray Companies
www.americanbankingnews.com - January 3 at 9:38 AM
Shire plc : Xiidra® Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease - GlobeNewswire (press release)Shire plc : Xiidra® Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease - GlobeNewswire (press release)
globenewswire.com - January 3 at 9:18 AM
Shire (SHPG) Lowered to "Sell" at Zacks Investment ResearchShire (SHPG) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
ValuEngine Downgrades Shire (SHPG) to HoldValuEngine Downgrades Shire (SHPG) to Hold
www.americanbankingnews.com - January 1 at 10:38 AM
Shire Plc :SHPG-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Shire Plc :SHPG-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 9:53 AM
FY2017 Earnings Forecast for Shire PLC (SHPG) Issued By Cantor FitzgeraldFY2017 Earnings Forecast for Shire PLC (SHPG) Issued By Cantor Fitzgerald
www.americanbankingnews.com - December 29 at 6:32 AM
Protalix (PLX) Fabry Disease Candidate Gets Orphan StatusProtalix (PLX) Fabry Disease Candidate Gets Orphan Status
finance.yahoo.com - December 28 at 10:36 AM
Brokers Offer Predictions for Shire PLCs FY2018 Earnings (SHPG)Brokers Offer Predictions for Shire PLC's FY2018 Earnings (SHPG)
www.americanbankingnews.com - December 27 at 10:08 PM
What Shire Is Planning With Its Newest FDA SubmissionWhat Shire Is Planning With Its Newest FDA Submission
247wallst.com - December 27 at 5:43 PM
ETFs with exposure to Shire Plc : December 27, 2017ETFs with exposure to Shire Plc : December 27, 2017
finance.yahoo.com - December 27 at 5:43 PM
Shire (SHPG) Given a $222.00 Price Target at Cantor FitzgeraldShire (SHPG) Given a $222.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - December 27 at 9:53 AM
Research Analysts Offer Predictions for Shire PLCs FY2017 Earnings (SHPG)Research Analysts Offer Predictions for Shire PLC's FY2017 Earnings (SHPG)
www.americanbankingnews.com - December 25 at 1:36 AM
Rare-Disease Portfolio Digs Shire a MoatRare-Disease Portfolio Digs Shire a Moat
finance.yahoo.com - December 22 at 10:07 AM
Traders Purchase High Volume of Put Options on Shire (SHPG)Traders Purchase High Volume of Put Options on Shire (SHPG)
www.americanbankingnews.com - December 22 at 3:26 AM
Shire PLC (SHPG) Given Average Rating of "Hold" by BrokeragesShire PLC (SHPG) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 21 at 1:42 PM
Shire plc (NASDAQ:SHPG): What Can We Expect From This High Growth Stock?Shire plc (NASDAQ:SHPG): What Can We Expect From This High Growth Stock?
finance.yahoo.com - December 21 at 9:59 AM
Interesting SHPG Put And Call Options For February 2018Interesting SHPG Put And Call Options For February 2018
www.nasdaq.com - December 20 at 4:52 PM
Shire (SHPG) Earns "Hold" Rating from Liberum CapitalShire (SHPG) Earns "Hold" Rating from Liberum Capital
www.americanbankingnews.com - December 20 at 10:40 AM
Shires stock falls after drug trial misses primary and secondary endpoints - MarketWatchShire's stock falls after drug trial misses primary and secondary endpoints - MarketWatch
www.marketwatch.com - December 20 at 10:02 AM
Whats Happening With These Drug Makers Stocks? -- Immune Pharmaceuticals, Zogenix, Shire, and Merck - PR Newswire (press release)What's Happening With These Drug Makers Stocks? -- Immune Pharmaceuticals, Zogenix, Shire, and Merck - PR Newswire (press release)
www.prnewswire.com - December 19 at 4:53 PM
Comparing Immune Pharmaceuticals (IMNP) and Shire (SHPG)Comparing Immune Pharmaceuticals (IMNP) and Shire (SHPG)
www.americanbankingnews.com - December 19 at 11:24 AM
Shire plc : Director DeclarationShire plc : Director Declaration
finance.yahoo.com - December 19 at 10:00 AM
Shires Hunter syndrome drug fails late-stage studyShire's Hunter syndrome drug fails late-stage study
finance.yahoo.com - December 19 at 10:00 AM
Shires stock falls after drug trial misses primary and secondary endpointsShire's stock falls after drug trial misses primary and secondary endpoints
finance.yahoo.com - December 19 at 10:00 AM
Shire says Hunter syndrome treatment fails in key studyShire says Hunter syndrome treatment fails in key study
finance.yahoo.com - December 19 at 10:00 AM
Roche, Shire court fight escalates over haemophilia drugRoche, Shire court fight escalates over haemophilia drug
finance.yahoo.com - December 16 at 10:01 AM
Shire PLC (SHPG) Sees Large Increase in Short InterestShire PLC (SHPG) Sees Large Increase in Short Interest
www.americanbankingnews.com - December 15 at 2:04 AM
Shire plc : Novel Clinical Study Collaboration Announced Designed to Improve Clinical Care for Hemophilia Patients through Innovative Personalized TreatmentShire plc : Novel Clinical Study Collaboration Announced Designed to Improve Clinical Care for Hemophilia Patients through Innovative Personalized Treatment
feeds.benzinga.com - December 14 at 7:52 AM
Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in EuropeShire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe
www.nasdaq.com - December 13 at 10:19 AM
Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)
feeds.benzinga.com - December 13 at 4:34 AM
Shire PLC (SHPG) Expected to Announce Quarterly Sales of $4.02 BillionShire PLC (SHPG) Expected to Announce Quarterly Sales of $4.02 Billion
www.americanbankingnews.com - December 12 at 3:48 AM
Shire (SHPG) a Sell on Sagging Quant ScoreShire (SHPG) a Sell on Sagging Quant Score
investorplace.com - December 11 at 3:49 PM
Wired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill TechnologyWired News – Shire and Rani Therapeutics Entered into Collaboration to Evaluate Use of the Rani Pill Technology
finance.yahoo.com - December 7 at 10:17 AM
Critical Survey: Shire (SHPG) versus Warner Chilcott (WCRX)Critical Survey: Shire (SHPG) versus Warner Chilcott (WCRX)
www.americanbankingnews.com - December 6 at 7:52 AM
Rani Therapeutics, Shire Partner To Develop Oral FVIII Delivery - Quick FactsRani Therapeutics, Shire Partner To Develop Oral FVIII Delivery - Quick Facts
www.nasdaq.com - December 5 at 10:41 AM
How Financially Strong Is Shire plc (LSE:SHP)?How Financially Strong Is Shire plc (LSE:SHP)?
finance.yahoo.com - December 5 at 10:41 AM

SEC Filings

Shire (NASDAQ:SHPG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Shire (NASDAQ:SHPG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Shire (NASDAQ SHPG) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.